BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

Nearly 20 years since the launch of Ablynx, VIB has spun out its fourth company with a camelid-derived antibody platform and its first to deploy the technology as a countermeasure against pandemic threats. ExeVir, which...
BioCentury | Feb 26, 2020
Product Development

U.S. testing of coronavirus vaccine, therapeutic begin

NIH is kicking off the first U.S. clinical trials for COVID-19 with an adaptive trial of remdesivir, an antiviral therapeutic, and a Phase I trial of Moderna’s vaccine candidate. Separately Tuesday, FDA Commissioner Stephen Hahn...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

BioCentury, like the biomedical innovation ecosystem it serves, is relentlessly focused on the future, but the turn of a decade is a good time to check in on the progress industry has made possible --...
BioCentury | Jun 3, 2019
Product Development

There are opportunities to eradicate opioid misuse: Investors and innovators should seize them

Eradicating opioid misuse and addiction will take an integrated, holistic approach involving prevention, treatment, and recovery. Crucially, it will also take the help of investors and innovators in biotechnology who understand the challenges and opportunities...
BioCentury | Feb 6, 2019
Politics & Policy

Trump announces HIV, children’s cancer initiatives

In the State of the Union speech, President Donald Trump announced initiatives to slash the rate of HIV transmission in the U.S. and to increase investments in research to treat pediatric cancer. The HIV initiative...
BioCentury | Dec 22, 2017
Product R&D

Dengvaxia’s warning

The fallout of Sanofi’s dengue vaccine debacle has researchers scrambling to rationalize whether competitor products will fall afoul of the same effects, and whether other, related fields should change course. The early upshot is that...
BioCentury | Nov 30, 2017
Clinical News

Otonomy's Meniere’s disease candidate meets in Phase III

Otonomy Inc. (NASDAQ:OTIC) reported top-line data from the double-blind, European Phase III AVERTS-2 trial in 174 patients with unilateral Meniere’s disease showing that a single 12 mg intratympanic injection of Otividex dexamethasone (OTO-104) met the...
BioCentury | Sep 30, 2017
Product Development

Running interference

Editor’s Note: An earlier version of this story was published in BioCentury on Sept. 25. It has been updated to include reporting about safety and efficacy data that was not included in the original. The...
BioCentury | Sep 1, 2017
Clinical News

Otonomy's Meniere’s disease candidate misses in Phase III

Otonomy Inc. (NASDAQ:OTIC) reported data from the double-blind, U.S. Phase III AVERTS-1 trial in 165 patients with unilateral Meniere’s disease who were experiencing 4 to 22 days with definitive vertigo episodes of >20 minutes showing...
BioCentury | Aug 30, 2017
Clinical News

Otonomy falls after Phase III Meniere’s disease failure

Otonomy Inc. (NASDAQ:OTIC) plummeted $17.22 (83%) to $3.58 after it said Otividex dexamethasone (OTO-104) missed the primary endpoint in the U.S. Phase III AVERTS-1 study to treat unilateral Meniere’s disease. The company, which lost $521.8...
Items per page:
1 - 10 of 50